Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

232
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
232
Cancer Survival Analysis01:21

Cancer Survival Analysis

562
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
562
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

115
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
115
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

450
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
450
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

102
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
102

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pragmatic Clinical Trial of Fostamatinib as Second-Line Therapy in Adult Patients With Immune Thrombocytopenia and Insufficient Response to Prior Therapy: The Fostamatinib FORTE Trial.

EJHaem·2026
Same author

Time-to-start of anticoagulant therapy and mortality in pulmonary embolism.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Bridging evidence and practice: the role of implementation science to optimize plasma transfusion in cirrhosis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Optimizing pulmonary embolism response team functionality: Outcomes of mechanical thrombectomy by interventional radiology and vascular surgery.

Vascular medicine (London, England)·2026
Same author

DOACs in cirrhosis: Progress, pitfalls, and the path forward.

Thrombosis research·2026
Same author

Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Dec 10, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.6K

Statins Reduce Mortality in Multiple Myeloma: A Population-Based US Study.

Amber Afzal1, Mark A Fiala2, Brian F Gage3

  • 1Division of Hematology, Department of Medicine, Washington University in St Louis, St Louis, MO.

Clinical Lymphoma, Myeloma & Leukemia
|September 2, 2020
PubMed
Summary

Statins may lower mortality risk in multiple myeloma patients. This study found statin use associated with a 21% reduced risk of death in all myeloma patients.

Keywords:
Mevalonic acid metabolismMortalityMultiple myelomaNovel agentsStatins

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.7K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Related Experiment Videos

Last Updated: Dec 10, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.7K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Area of Science:

  • Oncology
  • Pharmacology
  • Epidemiology

Background:

  • Multiple myeloma is a cancer of plasma cells.
  • Statins are commonly used cholesterol-lowering drugs.
  • The impact of statins on multiple myeloma mortality is not fully understood.

Purpose of the Study:

  • To investigate the association between statin use and mortality in a large cohort of multiple myeloma patients.
  • To explore the potential benefits of statins in patients treated with novel therapeutic agents.

Main Methods:

  • Utilized the SEER-Medicare database (2007-2013) for a nationally representative sample of multiple myeloma patients.
  • Employed multivariate Cox proportional hazards regression to analyze the association of statins with mortality.
  • Conducted subanalyses to assess statin effects in patients receiving novel agents.

Main Results:

  • Statin use was linked to a 21% reduction in mortality risk among all multiple myeloma patients (aHR=0.79, 95% CI 0.74-0.84).
  • In patients treated with novel agents (n=3603), statins demonstrated a 10% reduction in mortality risk (aHR=0.90, 95% CI 0.83-0.98).

Conclusions:

  • Statin use appears to be associated with improved survival in patients diagnosed with multiple myeloma.
  • Further research may elucidate the specific mechanisms and optimal use of statins in multiple myeloma management.